CGON CG Oncology Inc.
Price Chart
Executive Summary
CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at 6 months and 85.7% CR in CIS patients, with no grade 3+ TRAEs. The data support a potential intravesical combination regimen but remain early and require durability follow-up.
Actionable Insight
The strong Phase 2 data enhance the probability of success for cretostimogene in high-risk NMIBC, but the stock already reflects significant optimism (95% analyst buy). Watch for durability data later this year and next catalysts from Phase 3 trials (BOND-003, PIVOT-006).
Key Facts
- HG-EFS of 96.0% at 3 months and 89.5% at 6 months in ITT population (median follow-up 6.6 months)
- CR rate of 85.7% in CIS-containing ITT population (95% CI 67.3%-96.0%) and 92.3% in efficacy-evaluable population (95% CI 74.9%-99.1%)
- No grade 3 or greater treatment-related adverse events reported; favorable safety profile
- Data to be presented at AUA 2026; durability data expected later in 2026
Financial Impact
Positive read-through for cretostimogene's commercial potential in NMIBC; no revenue impact yet as product remains investigational
Risk Factors
- Early data with small sample size (28 CIS patients); durability results could disappoint
- Phase 3 trials (BOND-003, PIVOT-006) still ongoing and may not replicate these results
- Competitive landscape includes other intravesical therapies (e.g., retifanlimab, targeted agents)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295777 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $57.69 awaiting T+5 | awaiting T+5 | — | $59.56 (+3.24%) |
|
May 26, 2026
19d ago
|
8-K
| $61.89 $59.23 | ▼ −4.30% | ▼ −5.38% | $59.56 (−3.76%) |
|
May 15, 2026
4w ago
|
Press Release
| $66.93 $64.25 | ▼ −4.00% | ▼ −4.97% | $59.56 (−11.01%) |
|
May 8, 2026
5w ago
|
8-K
| $69.62 $69.54 | ▼ −0.12% | ▼ −1.59% | $59.56 (−14.45%) |
|
May 8, 2026
5w ago
|
Press Release
| $69.62 $69.54 | ▼ −0.12% | ▼ −1.59% | $59.56 (−14.45%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $66.82 $67.70 | ▲ +1.32% | ▲ +0.92% | $59.56 (−10.87%) |
|
Apr 17, 2026
8w ago
|
144
| $70.40 $66.82 | ▼ −5.09% | ▼ −6.00% | $59.56 (−15.40%) |
|
Apr 13, 2026
8w ago
|
8-K
| $67.70 $70.40 | ▲ +3.99% | ▲ +0.69% | $59.56 (−12.02%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $57.76 $61.29 | ▲ +6.11% | ▲ +7.32% | $59.56 (+3.12%) |
|
Feb 27, 2026
15w ago
|
Press Release
| $58.80 $61.88 | ▲ +5.24% | ▲ +7.22% | $59.56 (+1.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access